186 related articles for article (PubMed ID: 27665497)
1. A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK.
Salas-Vega S; Bertling A; Mossialos E
Health Policy; 2016 Oct; 120(10):1104-1114. PubMed ID: 27665497
[TBL] [Abstract][Full Text] [Related]
2. Commonalities and differences in HTA outcomes: a comparative analysis of five countries and implications for coverage decisions.
Nicod E; Kanavos P
Health Policy; 2012 Dec; 108(2-3):167-77. PubMed ID: 23088802
[TBL] [Abstract][Full Text] [Related]
3. Health benefit assessment of pharmaceuticals: An international comparison of decisions from Germany, England, Scotland and Australia.
Fischer KE; Heisser T; Stargardt T
Health Policy; 2016 Oct; 120(10):1115-1122. PubMed ID: 27628196
[TBL] [Abstract][Full Text] [Related]
4. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
5. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
Nicod E
Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
[TBL] [Abstract][Full Text] [Related]
6. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
[TBL] [Abstract][Full Text] [Related]
7. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.
Ball G; Levine MAH; Thabane L; Tarride JE
Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879
[TBL] [Abstract][Full Text] [Related]
8. Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: A mixed methods study.
Nicod E; Kanavos P
Health Policy; 2016 Jan; 120(1):35-45. PubMed ID: 26723201
[TBL] [Abstract][Full Text] [Related]
9. Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions.
Wong CKH; Wu O; Cheung BMY
Appl Health Econ Health Policy; 2018 Feb; 16(1):5-14. PubMed ID: 28702874
[TBL] [Abstract][Full Text] [Related]
10. [The role of HTA in German health care. Do we need impact objectives?].
Gerhardus A
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Mar; 49(3):233-40. PubMed ID: 16453136
[TBL] [Abstract][Full Text] [Related]
11. Toward a sustainable European Network for Health Technology Assessment. The EUnetHTA project.
Kristensen FB; Chamova J; Hansen NW
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Mar; 49(3):283-5. PubMed ID: 16453137
[TBL] [Abstract][Full Text] [Related]
12. An International Review of Health Technology Assessment Approaches to Prescription Drugs and Their Ethical Principles.
Rand LZ; Kesselheim AS
J Law Med Ethics; 2020 Sep; 48(3):583-594. PubMed ID: 33021189
[TBL] [Abstract][Full Text] [Related]
13. Health technology assessment of medical devices: What is different? An overview of three European projects.
Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
[TBL] [Abstract][Full Text] [Related]
14. [Health economics and HTA].
Kulp W; Greiner W
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Mar; 49(3):257-63. PubMed ID: 16465516
[TBL] [Abstract][Full Text] [Related]
15. Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries.
Visintin E; Tinelli M; Kanavos P
Health Policy; 2019 Feb; 123(2):118-129. PubMed ID: 30227974
[TBL] [Abstract][Full Text] [Related]
16. Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations.
Vreman RA; Mantel-Teeuwisse AK; Hövels AM; Leufkens HGM; Goettsch WG
Value Health; 2020 Jan; 23(1):10-16. PubMed ID: 31952664
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation and health care decision-making.
Rutten F
Health Policy; 1996 Jun; 36(3):215-29. PubMed ID: 10158267
[TBL] [Abstract][Full Text] [Related]
18. [Epidemiological studies in the HTA evaluation process].
Behrens T; Ahrens W
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Mar; 49(3):264-71. PubMed ID: 16477457
[TBL] [Abstract][Full Text] [Related]
19. Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies.
Makady A; Ham RT; de Boer A; Hillege H; Klungel O; Goettsch W;
Value Health; 2017 Apr; 20(4):520-532. PubMed ID: 28407993
[TBL] [Abstract][Full Text] [Related]
20. Determinants of Managed Entry Agreements in the context of Health Technology Assessment: a comparative analysis of oncology therapies in four countries.
Efthymiadou O; Kanavos P
Int J Technol Assess Health Care; 2021 Jan; 37():e31. PubMed ID: 33509311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
